KIT and acute myeloid leukemia: In addition, numerous clinical studies have proven the role of tumor suppressor genes such as TP53 and WT1 in cytogenetic normal AML (CN-AML) [21–24] and C-KIT in core binding factor AML (CBF-AML) [25].